Ex-officer plans $10.2M Adaptive Biotech share sale

Adaptive Biotechnologies Corp (ADPT) reports that former officer Harlan Robins plans to sell up to 402160 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, with an aggregate market value of 10230950.4.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (ADPT) reports that former officer Harlan Robins plans to sell up to 402160 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, with an aggregate market value of 10230950.4. These shares were acquired on 03/04/2022 as compensation via stock options and are designated for a cashless exercise / same-day sale. The notice also lists multiple prior open-market sales of Adaptive Biotechnologies common stock by Robins during the past three months.

Key Figures

Shares to be sold under Rule 144: 402160 shares Aggregate market value of planned sale: 10230950.4 Shares outstanding: 159595842 shares +4 more

7 metrics

Shares to be sold under Rule 144 402160 shares Planned sale of Adaptive Biotechnologies common stock by Harlan Robins

Aggregate market value of planned sale 10230950.4 Value associated with 402160 shares to be sold

Shares outstanding 159595842 shares Shares of Adaptive Biotechnologies common stock referenced in Form 144

Sale on 07/02/2026 250000 shares for 5565550 Common stock sale by Harlan Robins on 07/02/2026

Sale on 07/21/2026 284800 shares for 6225728 Common stock sale by Harlan Robins on 07/21/2026

Sale on 08/18/2026 261044 shares for 6411240.64 Common stock sale by Harlan Robins on 08/18/2026

Sale on 08/19/2026 215632 shares for 5496459.68 Common stock sale by Harlan Robins on 08/19/2026

Key Terms

Rule 144, cashless exercise, same-day sale, aggregate market value, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

same-day sale financial

"Compensation -- Cashless exercise / same-day sale"

aggregate market value financial

"402160 | 10230950.4 | 159595842 | 08/20/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Former Officer regulatory

"Former Officer 144: Securities Information"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Adaptive Biotechnologies (ADPT) disclosing about Harlan Robins in this Form 144?

Adaptive Biotechnologies discloses that former officer Harlan Robins intends to sell up to 402160 shares of its common stock under Rule 144 through Goldman Sachs & Co. LLC, based on shares acquired as compensation via stock options on 03/04/2022.

How many ADPT shares are covered by the planned Rule 144 sale?

The planned Rule 144 transaction covers up to 402160 shares of Adaptive Biotechnologies common stock, with an indicated aggregate market value of 10230950.4 and reference to 159595842 shares outstanding at the time of the notice.

How were the ADPT shares to be sold by Harlan Robins acquired?

The shares to be sold by Harlan Robins were acquired on 03/04/2022 as compensation through stock options. The planned disposition method is described as a compensation -- cashless exercise / same-day sale by the issuer’s former officer.

Which broker is handling the planned ADPT share sale for Harlan Robins?

The planned sale of Adaptive Biotechnologies common stock for Harlan Robins will be handled by Goldman Sachs & Co. LLC, located at 200 West Street, New York, New York, with the securities listed as trading on NASD.

What recent ADPT stock sales by Harlan Robins are disclosed in the past 3 months?

Disclosed recent sales include, among others, 250000 shares for 5565550 on 07/02/2026, 284800 shares for 6225728 on 07/21/2026, and 261044 shares for 6411240.64 on 08/18/2026, along with several additional transactions.

When is the approximate date of the planned ADPT share sale under this Form 144?

The approximate date of sale for the planned Rule 144 transaction is listed as 08/20/2026. The Form 144 notice is signed by Goldman Sachs & Co. LLC on behalf of Harlan Robins on the same date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 06:07 PM Accepted by SEC EDGAR 08/20/2026 - 06:07 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001780851
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Adaptive Biotechnologies Corporation
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	1-206-659-0067
Name of Person for Whose Account the Securities are To Be Sold	Harlan Robins
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	402160	10230950.4	159595842	08/20/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/04/2022	Acquired as compensation -- Stock Options	The Issuer			402160	03/04/2022	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/15/2026	100000	1737460
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/16/2026	6160	110945.91
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	136240	2936094.62
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	250000	5565550
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	207600	4538136
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	284800	6225728
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/17/2026	152036	3765931.72
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/17/2026	148956	3689640.12
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/18/2026	261044	6411240.64
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/19/2026	215632	5496459.68

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Harlan Robins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)